InvestSMART

Optiscan Imaging Limited (ASX:OIL)

ALERT: Price-sensitive ASX Announcement for OIL
Current share price for OIL : $0.165 0.015 (10%)+
Announcement
Release
10 Sep 2026 8:48AM
Price at Release
$0.150
Full Release
download
Summary
Optiscan Imaging Ltd announced that its live digital pathology study with Australian Clinical Labs (ACL) has surpassed the 80-case milestone, with 84 cases imaged using the InForm™ platform at ACL’s flagship anatomical pathology laboratory in Western Australia. The study is validating InForm™ in a high-throughput, real-world pathology environment across a wide range of tissue types, organ systems and disease states, including malignant, premalignant, inflammatory, benign and normal samples, with the device producing real-time, slide-free, cellular-level images for comparison against conventional H&E-stained glass slides. Optiscan said the collaboration is generating clinical evidence to refine imaging protocols, support pathologist training, optimise workflow integration and underpin future regulatory submissions in Australia and the United States, while also strengthening the platform’s commercial readiness, scalability and appeal to pathology providers. Management described the milestone as evidence of InForm™’s maturity and potential to transform pathology workflows, and ACL said the study supports meaningful innovation while maintaining its focus on accurate, timely and high-quality patient diagnosis.
Key Points
  • Optiscan has successfully imaged 84 cases in its digital pathology study with Australian Clinical Labs.
  • The study is evaluating the InForm™ platform in a live, high-throughput anatomical pathology laboratory in Western Australia.
  • Cases span multiple tissue types, organ systems and pathology categories, including cancerous and non-cancerous samples.
  • InForm™ provides real-time, slide-free, cellular-level imaging for comparison with conventional H&E-stained glass slides.
  • The collaboration is generating real-world data to refine imaging protocols, support pathologist training and improve workflow integration.
  • The study is expected to support future regulatory submissions in Australia and the United States.
  • Optiscan said the milestone improves commercial readiness and strengthens the case for broader adoption of its digital pathology technology.
  • ACL said the collaboration reflects its commitment to clinically meaningful innovation and better patient care.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.